Portal de Periódicos da CAPES

Cyclosporine and Itraconazole Interaction in Heart and Lung Transplant Recipients

1990; American College of Physicians; Volume: 113; Issue: 4 Linguagem: Inglês

10.7326/0003-4819-113-4-327

1539-3704

Mordechai R. Kramer, Sara E. Marshall, David W. Denning, Anne Keogh, Richard Tucker, John N. Galgiani, Norman J. Lewiston, David A. Stevens, James Theodore,

Renal Transplantation Outcomes and Treatments

Brief Reports15 August 1990Cyclosporine and Itraconazole Interaction in Heart and Lung Transplant RecipientsMordechai R. Kramer, MD, Sara E. Marshall, MBBCh, David W. Denning, MBBS, Anne M. Keogh, MBBS, Richard M. Tucker, MD, John N. Galgiani, MD, Norman J. Lewiston, MD, David A. Stevens, MD, James Theodore, MDMordechai R. Kramer, MD, Sara E. Marshall, MBBCh, David W. Denning, MBBS, Anne M. Keogh, MBBS, Richard M. Tucker, MD, John N. Galgiani, MD, Norman J. Lewiston, MD, David A. Stevens, MD, James Theodore, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-113-4-327 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptItraconazole is a new triazole antifungal (1-3). The infrequency of serious toxicity makes it particularly appropriate in patients receiving cyclosporine therapy, in whom nephrotoxicity is common. A related drug, ketoconazole, interacts significantly with cyclosporine (4). However, no interaction has been clearly documented between itraconazole and cyclosporine. We recently treated seven patients with itraconazole for serious fungal infections after heart-lung, heart, or lung transplantation. We observed an interaction between itraconazole and cyclosporine with subsequent impairment of patient renal function.Case ReportsFour heart-lung, two heart, and one lung transplant recipients were treated with itraconazole (Janssen Pharmaceutica, Beerse, Belgium) for aspergillosis (five...References1. Denning D, Tucker R, Hanson L, and Stevens D. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989;86:791-800. CrossrefMedlineGoogle Scholar2. Tucker R, Williams P, Arathoon E, and Stevens D. Treatment of mycoses with itraconazole. Ann NY Acad Sci. 1988;544:451-70. CrossrefMedlineGoogle Scholar3. Dupont B and Drouhet E. Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. Rev Infect Dis. 1987;9:S71-6. CrossrefMedlineGoogle Scholar4. Ferguson R, Sutherland D, Simmons R, and Najarian J. Ketoconazole, cyclosporine metabolism, and renal transplantation [Letter]. Lancet. 1982;1:882-3. CrossrefGoogle Scholar5. Cockburn I and Krupp P. An appraisal of drug interaction with Sandimmun. Transplant Proc. 1989;21:3845-50. MedlineGoogle Scholar6. Whiting P, Thomson A, and Simpson J. Cyclosporine: toxicity, metabolism, and drug interactions—implication from animal studies. Transplant Proc. 1985;17(Suppl):134-44. MedlineGoogle Scholar7. Lavrijsen K, van Houdt J, Thijs D, Meuldermans W, and Heykants J. Interaction of miconazole, ketoconazole and itraconazole with rat-liver microsomes. Xenobiotica. 1987;17:45-57. CrossrefMedlineGoogle Scholar8. Damanhouri Z, Gumbleton M, Nicholls P, and Shaw M. In-vivo effects of itraconazole on hepatic mixed-function oxidase. J Antimicrob Chemother. 1988;21:187-94. CrossrefMedlineGoogle Scholar9. Shaw M, Gumbelton M, and Nicholls P. Interaction of cyclosporine and itraconazole [Letter]. Lancet. 1987;1:637. Google Scholar10. Kwan J, Foxall P, Davidson D, Bending M, and Eisinger A. Interaction of cyclosporine and itraconazole [Letter]. Lancet. 1987;1: 282. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Mordechai R. Kramer, MD; Sara E. Marshall, MBBCh; David W. Denning, MBBS; Anne M. Keogh, MBBS; Richard M. Tucker, MD; John N. Galgiani, MD; Norman J. Lewiston, MD; David A. Stevens, MD; James Theodore, MDFrom Stanford University Medical Center, Stanford, California; Santa Clara Valley Medical Center, San Jose, California; the Mycoses Study Group, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland; and the University of Arizona College of Medicine, Tucson, Arizona. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDiagnosis and Treatment of Fungal Infections in Lung Transplant RecipientsTherapeutic drug monitoring for antifungal triazoles: pharmacologic background and current statusInteractions between anti‐infective agents and immunosuppressants—Guidelines from the American Society of Transplantation Infectious Diseases Community of PracticeEndemic Mycoses in Solid Organ Transplant RecipientsPharmacokinetics of antifungal drugs: practical implications for optimized treatment of patientsItraconazoleClinical Pharmacology of Itraconazole in Children and AdolescentsAntifungal AgentsRespiratory Failure due to Possible Donor-Derived Sporothrix schenckii Infection in a Lung Transplant RecipientUltra-performance liquid chromatography electrospray ionization–tandem mass spectrometry method for the simultaneous determination of itraconazole and hydroxy itraconazole in human plasmaAntifungal prophylaxis in lung transplantationVoriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interactionAntifungal AgentsAntifungal Treatment of Small Animal Veterinary PatientsManagement of Drug and Food Interactions with Azole Antifungal Agents in Transplant RecipientsAntifungal Agents and Antifungal Susceptibility TestingIMMUNE MODULATORSANTIFUNGAL DRUGSDrug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazoleOverview of Antifungal AgentsAzolesINFECTIONS IN PEDIATRIC HEART TRANSPLANTATIONANTIFUNGAL AGENTSRole of IL-10 in invasive aspergillosis: increased resistance of IL-10 gene knockout mice to lethal systemic aspergillosisEffects of Cyclosporine A on Single-Dose Pharmacokinetics of Intravenous Itraconazole in Patients With Hematologic MalignanciesBlood Concentration Curve of Cyclosporine: Impact of Itraconazole in Lung Transplant RecipientsOptimizing the use of cyclosporin in allogeneic stem cell transplantationA rapid HPLC method with fluorometric detection for determination of plasma itraconazole and hydroxy-itraconazole concentrations in cystic fibrosis children with allergic bronchopulmonary aspergillosisPharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic Hematopoietic Stem Cell Transplant RecipientsImpact of the cyclosporine-ketoconazole interaction in children with steroid-dependent idiopathic nephrotic syndromeItraconazoleAnimal models of Aspergillus infection in preclinical trials, diagnostics and pharmacodynamics: What can we learn from them?Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant PatientsItraconazole Prophylaxis in Lung Transplant Recipients Receiving Tacrolimus (FK 506): Efficacy and Drug InteractionDrug–drug interactions of antifungal agents and implications for patient careCurrent use of anti-infectives in dermatologyInvasive pulmonary aspergillosisCase StudyAzoles in the Management of Systemic Fungal InfectionsDrug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to knowTacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantationFungal Infections in Solid Organ Transplant PatientsPrimary Cutaneous Fungal Infections in Solid Organ Transplantation: A Case SeriesFungal Infections in the Immunocompromised HostAspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategiesEffect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjectsClotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patientsEnhanced cyclosporine-itraconazole interaction with cola in lung transplant recipientsApproach Towards Infectious Pulmonary Complications in Lung Transplant RecipientsAntifungal AgentsPharmacokinetic Aspects of Treating Infections in the Intensive Care UnitEfficacy and safety of Amphotericin B Lipid Complex Injection (ABLC) in solid-organ transplant recipients with invasive fungal infectionsEffects of the Antifungal Agents on Oxidative Drug MetabolismPrimary prophylaxis reduces fungal infections in transplant recipientsItraconazoleDrug interactions with itraconazole, fluconazole, and terbinafine and their managementAntifungal Prophylaxis During the Early Postoperative Period of Lung TransplantationItraconazole in Cyclodextrin SolutionCOADMINISTRATION OF NEORAL AND THE NOVEL RAPAMYCIN ANALOG, SDZ RAD, TO RAT LUNG ALLOGRAFT RECIPIENTSInvasive Aspergillosis in Transplant RecipientsAbsence of a dose-response of cyclosporine levels to clinically used doses of diltiazem and verapamilPreclinical and in vitro assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactionsAntifungal Agents. Part II. The AzolesUpdate on Drug Interactions with Azole Antifungal AgentsEffect of Metabolic Inhibitors on Cyclosporine Pharmacokinetics Using a Population ApproachInteraction Between Tacrolimus and Itraconazole in a Heart–Lung Transplant RecipientCurrent Issues in OnychomycosisClinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug DevelopmentContributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug deliveryDose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506)Biotransformation of Mestranol to Ethinyl Estradiol In Vitro: The Role of Cytochrome P-450 2C9 and Metabolic InhibitorsUse of Azoles for Systemic Antifungal TherapyInfections in solid-organ transplant recipientsConsiderations for Using Ketoconazole in Solid Organ Transplant Recipients Receiving Cyclosporine ImmunosuppressionConsiderations for using ketoconazole in solid organ transplant recipients receiving cyclosporine immunosuppressionNew Antifungal Drugs for Pulmonary MycosesFungal Infections in Lung and Heart-Lung Transplant Recipients: Report of 9 Cases and Review of the LiteratureThe Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral MidazolamThe Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral MidazolamUpdate on Invasive CandidiasisFUNGAL INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTSDrug interactions in transplantationPharmacologie des antifongiques azolés systémiquesTraitement des aspergilloses par l'itraconazoleKetoconazole to Reduce the Need for Cyclosporine after Cardiac TransplantationItraconazole for the treatment of histoplasmosis and blastomycosisAntifungal Drugs and ResistanceAntifungal chemotherapyAspergillose invasive en réanimationNIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosisAntifungal agents: An overview. Part IIItraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasmaItraconazole: A New Triazole Antifungal AgentTreatment of invasive aspergillosisEffect of Terbinafine on the Pharmacokinetics of Cyclosporin in HumansOral Azole Drugs as Systemic Antifungal TherapyFungal Infections in the Immunocompromised HostIbrotamidItraconazole-Digoxin InteractionJohn Rex, MDAzoles, a48 llylamines and drug metabolismControl of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patientAntifungal Agents Used for Deep-Seated Mycotic InfectionsCardiac Transplantation: A Review for the IntensivistsAntifungal chemotherapy — Are we winning?Correction: Spelling of "Coccidioidomycosis" 15 August 1990Volume 113, Issue 4Page: 327-329KeywordsAllergy and immunologyHeartHeart diseasesHeart-lung transplantationInfectious diseasesLongitudinal studiesLungsMycosesToxicityVeteran care ePublished: 1 December 2008 Issue Published: 15 August 1990 PDF downloadLoading ...